+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-Hodgkin Lymphoma Treatment Market - Global Forecast 2026-2032- Product Image
Non-Hodgkin Lymphoma Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Non-Hodgkin Lymphoma Treatment Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968597
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Non-Hodgkin Lymphoma Treatment Market is projected to reach USD 10.77 Billion in 2026. It is expected to continue growing at a CAGR of 9.12%, reaching USD 18.28 Billion by 2032.

Non-Hodgkin lymphoma (NHL) treatment is moving from broad chemoimmunotherapy toward biomarker-guided, immune-based, and cellular therapy strategies. The disease group spans more than 60 biologically distinct lymphoid malignancies, with diffuse large B-cell lymphoma and follicular lymphoma among the most common subtypes. According to IARC GLOBOCAN 2022, NHL accounted for more than 550,000 new cancer cases and roughly 250,000 deaths globally, underscoring the need for earlier diagnosis, durable remission, and wider access to advanced therapies.

Market momentum is supported by established anti-CD20 monoclonal antibodies, antibody-drug conjugates, BTK inhibitors, selective kinase inhibitors in defined settings, CAR T-cell therapies, and CD20xCD3 bispecific antibodies. Treatment decisions increasingly depend on histology, stage, age, performance status, prior therapy, molecular risk, comorbidities, treatment intent, and access to specialized care infrastructure.

Transformative Shifts in the NHL Treatment Landscape

The NHL treatment landscape has undergone a structural shift as clinicians move beyond one-size-fits-all chemotherapy. Rituximab-based regimens remain foundational for many B-cell lymphomas, while newer agents such as antibody-drug conjugates, immunomodulatory combinations, bispecific antibodies, and CAR T-cell products have expanded options for relapsed or refractory disease. Regulatory decisions in the United States, Europe, Japan, China, and other major markets show increasing acceptance of subtype-specific evidence, accelerated pathways for high-unmet-need disease, and post-authorization requirements for longer-term safety and durability data.

This transformation is changing care pathways. Community oncology networks are managing more complex sequencing decisions, academic centers are scaling cellular therapy programs, and payers are scrutinizing real-world durability, toxicity management, and total cost of care. The next competitive frontier is not only efficacy but also outpatient feasibility, manufacturing reliability, minimal residual disease assessment, cytokine release syndrome management, neurotoxicity monitoring, and equitable access to advanced lymphoma treatment.

Cumulative Impact of Artificial Intelligence on NHL Care

Artificial intelligence is creating cumulative value across NHL diagnosis, treatment selection, clinical operations, and post-treatment monitoring. In pathology, AI-assisted image analysis can support lymphoma classification, proliferation scoring, and workflow triage, while radiomics and machine learning can enhance PET/CT interpretation and response assessment when validated against clinical standards such as Lugano criteria and established nuclear medicine practice.

AI is also improving trial matching, adverse event surveillance, pharmacovigilance, and real-world evidence generation by organizing structured and unstructured clinical data. Large language models and clinical decision-support tools can reduce administrative burden, but adoption must remain governed by data quality, bias testing, clinical validation, cybersecurity, explainability, and transparent oversight. In NHL, AI’s strongest near-term impact is expected where it complements hematopathologists, radiologists, pharmacists, and multidisciplinary tumor boards rather than replacing specialist judgment.

Key Regional Insights Across Global NHL Treatment Markets

North America remains a major innovation hub for NHL treatment because of strong oncology research funding, FDA-enabled accelerated approvals, CAR T-cell center capacity, and broad participation in cooperative group trials. The United States drives much of the clinical adoption of bispecific antibodies and cellular therapy, while Canada emphasizes evidence review, provincial reimbursement decisions, and standardized cancer agency pathways. Europe combines high clinical sophistication with cost-effectiveness scrutiny, especially across EU health technology assessment systems. The United Kingdom, Germany, France, Italy, and Spain support advanced lymphoma care, although reimbursement timing, hospital capacity, and access to CAR T-cell slots vary across countries.

Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, and Australia increase clinical trial activity, local biologics capacity, lymphoma guideline adoption, and access to targeted therapies. Latin America shows rising demand as Brazil and Mexico strengthen oncology services, but diagnosis, reimbursement, and access to advanced agents remain concentrated in metropolitan centers. The Middle East, particularly wealthier Gulf health systems, is investing in tertiary oncology infrastructure, precision diagnostics, and specialist referral pathways. Africa faces the widest access gaps, with late diagnosis, limited hematopathology capacity, affordability constraints, and uneven availability of essential cancer medicines making biosimilars, regional centers of excellence, telepathology, and public-sector oncology programs central to improving NHL treatment outcomes.

Key Group Insights for NHL Treatment Strategy

Within ASEAN, demand is shaped by population growth, expanding private hospital networks, medical travel, and uneven access to molecular diagnostics and advanced immunotherapies. Singapore, Thailand, and Malaysia act as regional care anchors, while broader ASEAN access depends on affordability, public procurement, biosimilar uptake, and hematology workforce expansion. The GCC is investing in tertiary oncology infrastructure, precision medicine, digital health, and referral pathways for complex lymphoma cases, supporting adoption of immunotherapies where reimbursement and specialist capacity are available.

The European Union offers a highly regulated but attractive environment where centralized drug approvals, evolving joint clinical assessment, pharmacovigilance standards, and national reimbursement systems influence launch sequencing. BRICS economies combine large patient pools with increasing domestic manufacturing, biosimilar development, and clinical trial participation, though access remains differentiated by income, region, and public insurance coverage. G7 countries remain central to R&D, regulatory precedent, guideline development, and premium therapy adoption. NATO countries overlap substantially with high-income Western markets, where oncology resilience, medicine supply security, cross-border research collaboration, and preparedness planning are increasingly strategic for uninterrupted NHL care.

Key Country Insights Shaping NHL Treatment Demand

The United States is the largest high-value NHL treatment market, supported by deep clinical trial networks, early adoption of CAR T-cell therapy and bispecific antibodies, comprehensive cancer centers, and strong specialty pharmacy infrastructure. Canada offers high-quality care through provincial systems but often experiences more deliberate reimbursement timelines and regional variation in access to advanced therapies. Mexico and Brazil face a growing lymphoma burden and improving oncology capacity, though access to molecular testing, cellular therapy, and novel biologics remains concentrated in major urban centers and private systems.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature hematology practice with payer-driven evidence requirements. Germany often provides early post-approval access under structured reimbursement processes, while the United Kingdom uses health technology assessment to determine NHS adoption. France, Italy, and Spain maintain strong lymphoma networks but balance innovation with budget impact and regional implementation. Russia has substantial clinical need but faces access variability, procurement complexity, and uneven availability of newer therapies. China is advancing rapidly through local innovation, domestic biologics, hospital expansion, and large-scale trial participation; India combines high unmet need with affordability constraints, diagnostic variability, and biosimilar opportunity. Japan, Australia, and South Korea are sophisticated markets with strong regulatory systems, high diagnostic standards, active clinical research, and growing use of targeted and immune-based NHL therapies.

Actionable Recommendations for NHL Industry Leaders

Industry leaders should prioritize evidence packages that demonstrate durable remission, safety, quality of life, treatment sequencing value, and health-system relevance across defined NHL subtypes. Real-world evidence should be built into launch planning, particularly for CAR T-cell therapies, bispecific antibodies, antibody-drug conjugates, and therapies moving into earlier lines of treatment.

Manufacturers, providers, and payers should expand partnerships that improve diagnostic accuracy, accelerate referral to lymphoma specialists, and enable outpatient administration where clinically appropriate. Investments in biosimilars, patient assistance, local manufacturing, cold-chain reliability, adverse event management training, and digital care coordination can widen access in cost-sensitive markets while preserving clinical quality and continuity of care.

Research Methodology

This executive summary is grounded in secondary research from recognized oncology and public health sources, including IARC GLOBOCAN, WHO resources, national cancer agencies, regulatory approval databases, peer-reviewed hematology literature, and established clinical guideline bodies such as NCCN, ESMO, ASH, and disease-specific lymphoma consensus publications.

The analysis synthesizes disease epidemiology, treatment innovation, regional access dynamics, reimbursement patterns, regulatory pathways, diagnostic infrastructure, and adoption barriers. Insights were assessed for consistency across credible sources, with emphasis on verifiable clinical developments, approved therapeutic classes, observable access trends, and published medical evidence rather than unsupported projections, market sizing, or forecast-based assumptions.

Conclusion: Strategic Outlook for NHL Treatment

Non-Hodgkin lymphoma treatment is entering a more precise and competitive era defined by immunotherapy, cellular therapy, targeted agents, biosimilars, and AI-enabled care optimization. The strongest opportunities will emerge where clinical innovation aligns with diagnostic capacity, reimbursement evidence, manufacturing reliability, specialist training, toxicity management, and equitable delivery.

Organizations that combine robust clinical differentiation with access-focused execution will be best positioned to support sustainable growth while improving outcomes for patients across mature and emerging oncology markets. As NHL care becomes increasingly personalized, success will depend on turning scientific progress into timely, affordable, and high-quality treatment pathways.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.3. Immunotherapy
7.4. Radiation Therapy
7.5. Stem Cell Transplant
7.6. Targeted Therapy
8. Non-Hodgkin Lymphoma Treatment Market, by Cell Type
8.1. Introduction
8.2. B-cell Lymphomas
8.2.1. Burkitt Lymphoma
8.2.2. Diffuse Large B-Cell Lymphoma (DLBCL)
8.2.3. Follicular Lymphoma
8.2.4. Mantle Cell Lymphoma
8.2.5. Marginal Zone Lymphoma
8.3. NK-cell Lymphomas
8.4. T-cell Lymphomas
8.4.1. Anaplastic Large Cell Lymphoma
8.4.2. Cutaneous T-Cell Lymphoma
8.4.3. Peripheral T-Cell Lymphoma
9. Non-Hodgkin Lymphoma Treatment Market, by Route of Administration
9.1. Introduction
9.2. Intravenous Infusion
9.3. Oral
9.4. Subcutaneous Injection
10. Non-Hodgkin Lymphoma Treatment Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Non-Hodgkin Lymphoma Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Cancer Treatment Centers
11.4. Hospitals
12. Non-Hodgkin Lymphoma Treatment Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Non-Hodgkin Lymphoma Treatment Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Non-Hodgkin Lymphoma Treatment Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. AstraZeneca PLC
16.3. Bayer AG
16.4. BeiGene, Ltd.
16.5. Bristol-Myers Squibb Company
16.6. Cipla Inc.
16.7. Dr. Reddy’s Laboratories Ltd.
16.8. Eli Lilly and Company
16.9. F. Hoffmann-La Roche Ltd
16.10. Gilead Sciences, Inc.
16.11. GlaxoSmithKline PLC
16.12. Hikma Pharmaceuticals PLC
16.13. Intas Pharmaceuticals Ltd.
16.14. Kyowa Kirin Co., Ltd.
16.15. Lupin Ltd.
16.16. Merck & Co., Inc.
16.17. Novartis AG
16.18. Salvavidas Pharmaceutical Pvt. Ltd.
16.19. Sanofi S.A.
16.20. Takeda Pharmaceutical Company Limited
16.21. Teva Pharmaceutical Industries Ltd.
16.22. Zydus Pharmaceuticals
List of Figures
FIGURE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RADIATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RADIATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL STEM CELL TRANSPLANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL STEM CELL TRANSPLANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL STEM CELL TRANSPLANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL B-CELL LYMPHOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL B-CELL LYMPHOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL B-CELL LYMPHOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL BURKITT LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL BURKITT LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL BURKITT LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL FOLLICULAR LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL FOLLICULAR LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL FOLLICULAR LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL MANTLE CELL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL MANTLE CELL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MANTLE CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MARGINAL ZONE LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MARGINAL ZONE LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MARGINAL ZONE LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL NK-CELL LYMPHOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL NK-CELL LYMPHOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL NK-CELL LYMPHOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL T-CELL LYMPHOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL T-CELL LYMPHOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL T-CELL LYMPHOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CUTANEOUS T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL CUTANEOUS T-CELL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CUTANEOUS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL PERIPHERAL T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PERIPHERAL T-CELL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PERIPHERAL T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CANCER TREATMENT CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER TREATMENT CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER TREATMENT CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 92. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 94. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 95. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 96. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 97. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 98. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 99. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 118. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 119. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 120. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 121. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 122. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 123. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 135. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 136. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 137. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 138. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 139. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 140. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 143. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 144. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 145. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 146. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 147. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 148. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 151. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 152. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 153. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 154. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 156. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 165. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 167. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 168. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 169. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 170. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 171. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 172. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 175. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 176. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 177. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 178. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 179. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 180. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 182. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 183. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 184. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 185. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 186. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 187. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 189. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 191. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 192. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 193. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 194. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 195. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 200. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 201. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 202. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 203. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 204. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 205. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 207. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 208. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 209. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 210. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 211. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 212. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 213. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 216. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 217. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 218. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 219. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 220. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 221. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 224. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 225. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 226. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 227. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 230. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 232. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 233. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 234. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 235. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 237. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 238. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 240. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 241. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 242. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 243. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 244. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 245. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 248. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 249. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 250. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 251. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 253. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 256. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 257. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 258. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 259. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 260. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 261. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 264. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 265. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 266. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 267. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 268. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 269. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 270. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 272. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 273. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 274. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 275. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 276. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 277. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 280. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 281. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 282. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 283. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 284. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 285. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 288. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 289. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 290. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 291. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 292. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 293. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 296. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2017-2032 (USD MILLION)
TABLE 297. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 298. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2017-2032 (USD MILLION)
TABLE 299. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 300. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 301. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 303. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Kyowa Kirin Co., Ltd.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages184
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 10.77 Billion
Forecasted Market Value ( USD ) by 2032 $ 18.28 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Lymphoma Therapeutics Market - Global Forecast 2026-2032 - Product Image

Lymphoma Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Hodgkin Lymphoma Treatment Market - Global Forecast 2026-2032 - Product Image

Hodgkin Lymphoma Treatment Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Non-Hodgkin Lymphoma Therapeutics - Global Strategic Business Report - Product Image

Non-Hodgkin Lymphoma Therapeutics - Global Strategic Business Report

  • Report
  • 176 Pages
  • Global
From
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 198 Pages
  • Global
From
Lymphoma Treatment Market Report by Type, Test Type, Drug, and Region 2026-2034 - Product Image

Lymphoma Treatment Market Report by Type, Test Type, Drug, and Region 2026-2034

  • Report
  • 143 Pages
  • Global
From

About the Market

The Non Hodgkin Lymphoma Drug market is a subset of the larger Lymphoma Drugs market. Non Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system, and is the seventh most common cancer in the United States. Treatment for NHL typically involves chemotherapy, radiation, and targeted therapies. The Non Hodgkin Lymphoma Drug market is composed of a variety of drugs used to treat NHL, including monoclonal antibodies, small molecule drugs, and immunomodulators. These drugs are used to target specific proteins and pathways involved in the development and progression of NHL. Some of the major companies in the Non Hodgkin Lymphoma Drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.